Considering that cancer patients treated with an OAC are at a high risk of bleeding, the duration of the P2Y12 inhibitor administration should be as short as possible after PCI or ACS, and then patients should continue with the OAC at the appropriate dose. Here, P2RY12 is linked to cancer.